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Summary
Objective: Intra-articular injection of hyaluronan (HA) is frequently used to treat knee osteoarthritis (OA). We studied whether HA injections
induced signiﬁcant changes in levels of biochemical markers in synovial ﬂuid (SF). In addition, we investigated the possibility of predicting
the effectiveness of HA based on these biochemical markers.
Methods: Twenty-eight patients with knee OA underwent ﬁve weekly intra-articular injections of HA. Knee pain was measured on visual
analog scale (VAS) before and after the ﬁve injections. Levels of biochemical markers, including chondroitin 6-sulfate (C6S), chondroitin
4-sulfate (C4S), keratan sulfate (KS), and tenascin-C (TN-C), were determined before and after the ﬁve injections. Correlations between
the biochemical markers before HA injection and the improvement of VAS after the ﬁve injections were evaluated.
Results: After HA injections, levels of C6S, C4S, and KS decreased signiﬁcantly. Inverse correlations were observed between the levels of
TN-C and C4S before HA injection and improvement of VAS after the ﬁve injections. In contrast, no signiﬁcant correlation was seen between
levels of C6S and KS before injections and improvement of VAS after the ﬁve injections.
Conclusion: The reduction in C6S, C4S, and KS levels after HA injections reﬂects that HA could help maintain normal cartilage metabolism.
Our ﬁndings suggest that HA injections are effective in patients whose knees contain low levels of TN-C and C4S, reﬂecting an early stage of
OA and limited synovitis.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Hyaluronan, Knee osteoarthritis, Biomarker, Synovial ﬂuid.Introduction
Osteoarthritis (OA) is one of themost prevalent diseases in the
aging population. This disease is characterized by changes in
cartilage, subchondral bone, and synovium. Secondary syno-
vitis resulting from the breakdown products of cartilage and
bone matrix likely modiﬁes the symptoms of OA. Articular car-
tilage is composed of chondrocytes embedded in an extracel-
lular matrix of principally type II collagen and proteoglycan
aggrecanmolecules1. The release of degraded aggrecanmol-
ecules containing glycosaminoglycans, including chondroitin
sulfate (CS)andkeratansulfate (KS), from thematrix into syno-
vial ﬂuid (SF) canbedetectedand levels of these twobiochem-
ical markers are reﬂective of aggrecan turnover2,3. Adult
human articular cartilagemainly contains chondroitin 6-sulfate
(C6S), which is converted to chondroitin 4-sulfate (C4S) in OA
cartilage4,5. In contrast, the synovium, meniscus, and liga-
ments predominantly contain the C4S isomer. KS is found al-
most exclusively in cartilage aggrecan6. Cartilage markers
are divided into markers of synthesis and catabolism. Typical*Address correspondence and reprint requests to: Dr Masahiro
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526markers of catabolism reﬂect the destruction of cartilage. Cat-
abolic markers include aggrecan molecules, CS, and KS. It is
not clear whether these markers reﬂect degradation of mature
resident proteoglycan or of newly synthesized molecules7.
Tenascin-C (TN-C) is a hexameric glycoprotein component
of the extracellular matrix. TN-C is up-regulated inmany path-
ologic adult conditions, including tumorigenesis, regenera-
tion, and inﬂammation8e10. We reported that TN-C levels of
theSFweresigniﬁcantly correlatedwith radiographicprogres-
sion of knee OA11. Further, we have recently shown that SF
levels of TN-Cwerehigher in patientswith rheumatoid arthritis
(RA) compared with patients with OA12. TN-C could thus be
a useful biochemical marker for OA and RA.
The intra-articular injection of hyaluronan (HA) has been ex-
tensivelyused in the treatmentofOA. In thisstudy,weobserved
whether repetitive intra-articular injectionsofHA in patientswith
OA induced signiﬁcant changes in SF levels of biochemical
markers, including C6S, C4S, KS, and TN-C. In addition, we
investigated the possibility of predicting the effectiveness of
HA based on levels of these biochemical markers in the SF.MethodsPATIENTS AND CLINICAL ASSESSMENTTwenty-eight patients fulﬁlling the American College of Rheumatology cri-
teria of knee OA13 underwent ﬁve weekly intra-articular injections of HA. The
Table I
SF levels of C6S, C4S, KS, and TN-C before HA injection (week 0)
and after five weekly injections (week 5)
Week 0 Week 5 P
C6S (nmol/ml) 61.2 35.8 52.8 25.3 0.012
C4S (nmol/ml) 19.1 6.7 17.8 6.1 0.044
KS (mg/ml) 6.1 3.1 5.2 2.9 <0.001
TN-C (ng/ml) 37.4 59.1 39.0 58.1 0.411
Results are mean standard deviation.
527Osteoarthritis and Cartilage Vol. 16, No. 4cohort consisted of 19 women and nine men whose mean age and body
mass index (BMI) were 76.7 years (range, 62e88 years) and 23.5 kg/m2
(range, 17.3e31.1 kg/m2), respectively. Most of the patients have no occupa-
tion with low activity. No concomitant steroid therapy or nonsteroidal anti-
inﬂammatory drugs were administered. Patients were divided into four
groups based on radiographic grading of the OA severity described by
Kellgren and Lawrence14. Two independent readers blinded to the source
of the data graded the knees. Two patients were grade 1, 12 were grade
2, nine were grade 3, and ﬁve were grade 4. All patients gave informed con-
sent, and this study was approved by the local ethics committee.
Patients were treated with ﬁve weekly intra-articular injections of 1% HA
(molecular weight about 900,000 Da) solution with a dosage of 2.5 mL/injec-
tion (Artz, Seikagaku Corporation, Tokyo, Japan). SF samples were col-
lected before each HA injection. The SF was centrifuged at 15,000 g for
15 min and the supernatants were stored at 80C until analyzed.
Knee pain was measured on a 100-mm visual analog scale (VAS;
0 mm¼ no pain, 100 mm¼worst imaginable pain) before the ﬁrst injection
and after ﬁve weekly injections of HA.MEASUREMENT OF BIOCHEMICAL MARKERSTN-C: R=-0.405, P=0.035
40
50
60
70
80
 V
A
S 
(m
m)C6S and C4S in the SF were measured by high performance liquid chro-
matography (HPLC) as described previously15,16. The SF samples were di-
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charide was calculated. KS levels were determined by HPLC according to
the method by Yamada et al.17. Brieﬂy, the SF samples were diluted 10-
fold and treated with keratanase II (Seikagaku Corporation) to be digested
to two disaccharide isomers, namely b-galactosyl-(1-4)-6-0-sulfo-N-acetylglu-
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Levels of large-subunit TN-C containing the ﬁbronectin type III (FNIII) C
domain were determined using an enzyme-linked immunosorbent assay
(ELISA) kit (IBL, Gunma, Japan) with two monoclonal antibodies, 4F10TT
and 19C4MS, as described previously11. Samples were diluted 10-fold and
incubated in 96-well ELISA plates coated with 19C4MS. After washing,
horseradish peroxidase-conjugated anti-TN-C Fab0 fragments (4F10TT
Fab0) were added. TN-C puriﬁed from conditioned media of human glioma
cells was used to prepare a standard curve.20
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ables were compared using a paired Wilcoxon test for the differences be-
tween pre- (week 0) and post-HA injection (week 5) values. A correlation
analysis was performed for VAS and SF levels of biochemical markers be-
fore injection using Spearman’s rank correlation test. Correlations between
levels of biochemical markers before injection and improvement of VAS
were also estimated. The KruskaleWallis test was used to determine the dif-
ference between radiographic stages of OA and improvement of VAS.
P values less than 0.05 were considered signiﬁcant.C4S: R=-0.409, P=0.034
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Fig. 1. Correlation between SF levels of TN-C and C4S before HA
injection and improvement of VAS after ﬁve weekly injections.
TN-C: R¼0.405, P¼ 0.035; C4S: R¼0.409, P¼ 0.034.Before the ﬁrst HA injection, signiﬁcant correlations were
found between C6S and C4S levels (R¼ 0.864, P< 0.001)
and between C6S and KS levels (R¼ 0.529, P¼ 0.006), but
not between KS and C4S levels (R¼ 0.319, P¼ 0.098).
The levels of TN-C correlated with C6S (R¼ 0.552,
P¼ 0.004) and C4S levels (R¼ 0.713, P< 0.001), but not
with KS levels (R¼ 0.087, P¼ 0.653). No signiﬁcant corre-
lations between VAS and levels of biochemical markers
were identiﬁed.CHANGES IN BIOCHEMICAL MARKERS AFTER HA INJECTIONSThe concentrations of C6S, C4S, and KS were signiﬁ-
cantly decreased after ﬁve weekly HA injections (Table I).
TN-C levels showed no changes before or after HA injec-
tions (Table I).CORRELATION BETWEEN BIOCHEMICAL MARKERS BEFORE
HA INJECTION AND IMPROVEMENT OF VASA signiﬁcant inverse correlation was observed between
the TN-C levels before HA injection and improvement of
VAS after ﬁve weekly HA injections (Fig. 1). The concentra-
tions of C4S before injection also showed an inverse corre-
lation with improvement of VAS after ﬁve weekly HA
injections (Fig. 1). In contrast, no signiﬁcant correlation
was seen between C6S and KS levels before injection
528 M. Hasegawa et al.: Biomarker changes and prediction of HA effectand improvement of VAS after ﬁve weekly HA injections
(C6S: P¼ 0.183; KS: P¼ 0.803). Radiographic stages of
OA had no signiﬁcant relation with improvement of VAS
(P¼ 0.201).
Discussion
Many randomized controlled studies have conﬁrmed that
intra-articular injections of HA can decrease knee pain in
patients with OA18e20. These studies showed that the efﬁ-
cacy of HA treatment was superior to placebo, and the
safety of HA treatment was also conﬁrmed18e21. HA be-
haves as a viscous liquid at low shear rates and as an elas-
tic solid at high shear rates. In addition to the rheological
functions, HA has a variety of effects on cells in vitro. It in-
hibits prostaglandin E2 synthesis induced by interleukin-1
(IL-1) and protects against proteoglycan release and cyto-
toxicity induced by oxygen-derived free radicals, IL-1, and
mononuclear cell-conditioned medium22. HA induces IL-1b,
tumor necrosis factor a, and insulin-like growth factor 1
messenger RNA transcript expression that are blocked by
monoclonal antibodies to the HA receptor CD 44 in mono-
cyte23. In cartilage, HA suppresses cartilage matrix degra-
dation24. HA has been shown to increase the synthesis of
proteoglycans and collagen25. In animal models, studies
attempting to ascertain whether intra-articular injections of
HA modify structural damage in the OA joint have produced
conﬂicting results. Numerous studies have shown that HA
injections prevent cartilage degradation and release of pro-
teoglycans26e30. HA has a positive effect on the mainte-
nance of cartilage matrix integrity during the development
of OA as well as on the reduction of synovitis28,31. However,
Smith et al.32 showed a striking reduction in proteoglycan
concentration in articular cartilage after HA injections in an
OA model. This ﬁnding raises the concern that HA treat-
ment could suppress the synthesis of proteoglycans and
accelerate joint damage. There is an increasing interest in
structure/disease modiﬁcation as the goal in OA treatment,
however, we have no universally proven structure-/disease-
modifying interventions33.
A signiﬁcant correlation between C6S and KS levels, but
not between KS and C4S levels has been reported by
others34 and was conﬁrmed in the present study. This cor-
relation is interesting, as C6S and KS are most concen-
trated in healthy adult human articular cartilage. In
contrast, in OA cartilage, there is an increased level of
C4S and a decreased level of C6S and KS. The proteogly-
can fragments observed in OA SF have characteristics of
degradation products of proteoglycan aggrecan molecules
that are released from the original resident matrix. Thus,
the disease process may be characterized by a continuing
attack on the original resident molecules. The reduction in
glycosaminoglycan levels in severe disease is probably as-
sociated with suppression of cartilage matrix turnover and
the loss of residual cartilage, as a decrease in C4S levels
as well as C6S levels is also observed at this stage5,35,36.
One of the most obvious uses of biochemical markers is
their potential to shed light on the effects of the treatment on
the metabolism of joint tissue. Based on changes in bio-
chemical marker levels after HA injections, the present
study showed that catabolic markers, including C6S, C4S,
and KS decreased after HA injections. Several previous
studies have studied SF markers in patients treated with
HA injections. Creamer et al.37 reported that a decrease
in KS levels occurred in knees treated with HA, although
their ﬁndings did not reach statistical signiﬁcance. Kobaya-
shi et al.38 showed that SF levels of C4S and C6S weresigniﬁcantly decreased after ﬁve weekly intra-articular injec-
tions of HA. The level of intact aggrecan was stable during
the series of HA injections in this study. This means that the
level of degraded aggrecan alone was reduced in the SF by
HA injections. The reduction in levels of CS and KS after HA
injections reﬂects that HA could inhibit the release of proteo-
glycans from degenerated cartilage, down-regulate the syn-
thesis of proteoglycans for the process of cartilage repair,
and maintain normal cartilage metabolism38,39. Smith
et al.32 found favorable effects of HA treatment on sup-
pressing proteoglycan synthesis after HA injections in an
OA model.
Changes in biochemical markers during the course of HA
treatment can help to determine the effectiveness of treat-
ment. Because joint puncture is an invasive procedure,
and has a risk of complications, including infection39, deter-
mining potential nonresponders can lead to more efﬁcient
use of HA. Only one previous study approached the predic-
tion of the effectiveness with HA injections for the treatment
of knee OA, and results showed positive correlations
between levels of C6S and aggrecan (molecules with
HA-binding ability and a KS side chain) before HA injection
and the improvement of clinical scores after injections39. Im-
provement of clinical symptoms after initiation of HA injec-
tion can be predicted by measurement of the fragments
derived from aggrecan. The authors concluded that HA in-
jections were effective for knees with high levels of aggre-
can fragments, reﬂecting an early stage of OA in keeping
with residual cartilage and chondrocyte metabolic activity.
However, the markers had no signiﬁcant relation with im-
provement of VAS. The present study is the ﬁrst, to our
knowledge, to show some prediction of the effectiveness
of HA injections for knee pain. However, limitations of this
study include a small sample size, limited follow-up period,
and absence of a control group.
Low levels of TN-C and C4S at baseline were associated
with decreasing pain. Previous studies revealed that TN-C
levels of SF were elevated in patients with advanced OA.
In addition, studies have shown that levels of TN-C and
C4S were higher in patients with RA compared with
OA12,16. It is possible that the proliferated synovium, as
well as degenerated cartilage, accelerates the release of
C4S into the SF. Our ﬁndings suggest that HA injections
are effective for knees with low levels of TN-C and C4S, re-
ﬂecting an early stage of OA and limited synovitis. Joint ﬂuid
analysis may provide useful information about the predic-
tion of the efﬁcacy at the time of the ﬁrst injection of HA.
Since blood or urine would have much wider application,
further studies are needed to ﬁnd blood or urine markers
to predict HA effectiveness before the ﬁrst injection.Conﬂict of interest statement
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